PNS Education Courses

The PNS sponsors educational activities consisting of symposia and teaching courses held at various Scientific Societies Congresses, as well as separate ad-hoc teaching courses prepared in collaboration with national societies; single lectures or clinical demonstrations.

If you or your organization would like to partner with the PNS, click here for more information.


Upcoming PNS Education Courses

EAN/PNS Joint Sessions & Teaching Course at the 9th Congress of the EAN

9th Congress of the European Academy of Neurology

Budapest, Hungary

1-4 July 2023

Earlybird Deadline: 26 April 2023

IaS01: EAN/PNS: Treatable inheritable neuropathies: things become real

Saturday, 1 Jul, 08:30 – 10:00 CEST

The aim of the session is to train clinicians in suspecting, diagnosing and treating hereditary neuropathies that commonly are misdiagnosed as more frequent conditions (either inherited or acquired) and are treatable. These include different metabolic disorders and proteinopathies, diagnoses which should not be missed.

TC05: EAN/PNS: Small fiber neuropathy – update on diagnosis and treatment (L1)

Saturday, 1 Jul, 15:30 – 18:45 CEST

Small fiber neuropathy is frequently suspected in patients with acral pain of unknown etiology. It can also accompany a number of systemic diseases. This course will give a comprehensive description of diagnostics, etiology, and treatment of small fiber neuropathy.

TC09: Diagnosis and treatment of GBS, CIDP and autoimmune nodopathies (L3)

Sunday, 2 Jul, 15:30 – 18:45 CEST

The new EAN/PNS GBS and CIDP diagnosis and treatment guidelines constructed by an international task force of disease experts according to modern GRADE methodology will be presented. The GBS guideline is the first ever and the CIDP guideline is a long awaited revised version of the 2010 guideline. The state-of-the-art management recommendations for GBS and CIDP will be discussed.

The autoimmune nodopathies, a novel group of neuropathies resembling CIDP but distinct from it, are caused by nodal/paranodal cell adhesion molecule antibodies mainly of the IgG4 subclass. The special features associated with these will be discussed as will be the treatment recommendations. Biomarkers helpful for the diagnosis and follow-up of these autoimmune neuropathies are being developed.

Together with an increasing number of validated outcome measures, they are helpful instruments to monitor the disease course and treatment response and to reshape treatment of CIDP and autoimmune nodopathies.

ST36: Scientific Theater Session: Advances in Guillain-Barré syndrome (GBS)

Monday, 3 Jul, 15:30 – 16:00 CEST

Guillain-Barré syndrome (GBS) is a heterogeneous disorder that requires early diagnosis and treatment. The new EAN/PNS GBS Guideline aids in the diagnostic process and treatment of GBS. An important other advance are results of the International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study. IGOS contains data and biological samples of 2000 patients included from over 140 centers across five continents. It enables to identify predictors of disease onset, subtype, course and outcome. Results and new possibilities using data of this large GBS study will be discussed.

The 15th Biennial Convention of the ASEAN Neurological Association 2023

The 15th Biennial Convention of the ASEAN Neurological Association 2023

Danang, Vietnam

10-13 August 2023


PNS/ASNA Joint Plenary Session

Saturday, 12 August 2023, 13.30 – 14.45 ICT


Chairs: Dr. Umapathi Thirugnanam (Singapore), Dr. Le Minh (Vietname)

  • Long Live the Art of Clinical Neuropathy
    Dr. Hadi Manji (UK)
  • COVID-19 and the PNS
    Dr. James Sejvar (US)
  • Title TBD
    Speaker TBD

PNS/NEUROdiab Joint Session at the 33rd Annual Meeting of NEUROdiab – the Diabetic Neuropathy Study Group

33rd Annual Meeting of the Diabetic Neuropathy Study Group

Thessaloniki, Greece

28 September – 1 October 2023

Early Bird Deadline 15 June 2023

PNS/NEUROdiab Joint Session

Saturday, 30 September 2023, 15.45 – 16.55 EEST

Insights Into the Nerve Damage in Diabetic Neuropathy
Chairs: Dr. Brian Callaghan (USA), Dr. Dinesh Selvarajah (UK)

  • The Role of Schwann Cell-Axon Interactions in Metabolic Disease
    Dr. Stephanie Eid (US)
  • The Role of Mitochondria and Bioenergetic Failure in Painful Neuropathy
    Dr. Daniela Menichella (US)
  • The Role of Nerve Vessels
    Dr. Zoltan Kender (Germany)

PNS Joint Session at the 2023 AANEM Annual Meeting

2023 AANEM Annual Meeting

Phoenix, Arizona, USA

1-4 November 2023

Registration is scheduled to open summer 2023.

Early-Bird Registration Deadline: August 15
Regular Registration Deadline: September 30
Late Registration Deadline: November 4

Updates on CMT, GBS, and Diabetic Neuropathy

Wednesday, 1 November 2023, 13:30 – 15:00 p.m. CST (US/Canada)

Speakers: Ruple S. Laughlin, MD; Vera Fridman, MD; Mazen M. Dimachkie, MD

Review advances in the development of treatments for Charcot Marie Tooth disease (CMT); discuss the activities and results of research collaborations through the International Guillain Barre Outcome Study (IGOS); and review the clinical picture, diagnosis and treatment of diabetic radiculoplexus neuropathy.

 This activity has been planned an implemented in accordance with the accreditation requirements and policies of the ACCME through joint provider ship of AANEM and the Peripheral Nerve Society. The AANEM is accredited by the ACCME to provide continuing medical education for physicians.

PNS/Society for Neuroscience (SFN) Roundtable at Neuroscience 2023

Society for Neuroscience: Neuroscience 2023

Washington, DC, USA

11-15 November 2023


Basic-Translational-Clinical Roundtables

Sunday, 12 November, 10.30 – 12.00 EST (US/Canada)

Chair: Ahmet Hoke, MD, PhD
Michael Coleman, PhD; Shilpa Sambashivan, PhD

Distal axon degeneration is a principal cellular event resulting in symptoms in peripheral neuropathies. In this rountable, advances in our understanding of the molecular mechanisms of programmed axon degeneration and its relevance to slow distal axon degeneration seen in peripheral neuropathies will be discussed and therapeutic targets and biomarkers will be highlighted.